Teva Pharma (TEVA) Tops Q1 EPS by 28c, Raises FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Teva Reports First Quarter 2018 Financial Results
May 3, 2018 7:00 AM EDTRevenues of $5.1 billion Free cash flow of $1.9 billion GAAP EPS of $1.03 Non-GAAP EPS of $0.94 Restructuring plan on-track to achieve $1.5 billion of savings in 2018 and $3.0 billion by the end of 2019 Raising 2018 full year guidance: Non-GAAP EPS guidance raised to $2.40-2.65 from $2.25-2.50 Free cash flow guidance raised to $3.0-3.2 billion from $2.6-2.8 billion
JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical... More
